Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | AXL Y779F |
Therapy | Cetuximab |
Indication/Tumor Type | head and neck squamous cell carcinoma |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
AXL Y779F | head and neck squamous cell carcinoma | resistant | Cetuximab | Preclinical - Cell culture | Actionable | In a preclinical study, Erbitux (cetuximab) treatment did not inhibit proliferation of head and neck squamous cell carcinoma cells expressing AXL Y779F in culture PMID: 32439698). | 32439698 |
PubMed Id | Reference Title | Details |
---|---|---|
(32439698) | AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. | Full reference... |